20岁开始秃顶的男士今后患前列腺癌的风险可能更高。这也许意味着年轻时秃顶的男性可以接受前列腺癌筛查,从而尽早发现这一疾病。研究报告由2月15日出版的最新一期法国Annals of Oncology发表。
巴黎笛卡尔大学教授菲利普·吉罗自2004年9月起带领同事进行这一研究。他们的研究对象为388名正在接受前列腺癌治疗男性与281名健康男性。
研究人员先让所有人填写调查问卷,回答有关患前列腺癌问题,然后让他们从四张不同程度秃顶照片中选择最能代表自己20、30及40岁头发状况的照片。这四张照片上的发型分别是正常、前额脱发、头顶脱发以及前额头顶均脱发。
研究人员还访问受访前列腺癌患者的医生,让他们提供患者相关资料,如病人患病类型、患病年龄、患病阶段以及治疗方法。
研究共进行28个月。这些前列腺癌患者的年龄为46至84岁。
研究人员对比后发现,患前列腺癌男性中,37人在20多岁时开始出现不同程度脱发,健康组中脱发的只有14人。
参与这一研究的加拿大蒙特利尔大学助理教授迈克尔·亚萨说,所有参与调查的志愿者中,只有三个人20岁时处于秃顶的第三阶段,即头顶脱发,没有人处于第四阶段,即前额头顶都脱发。但是统计数据显示,只要20多岁开始秃顶,无论处于哪一阶段,今后患前列腺癌的风险都会翻倍。
不过,那些30或40多岁才开始秃顶的男性患前列腺癌的风险与健康组相比并无差别。另外,开始秃顶时年龄小并不意味着患前列腺癌会更早。
亚萨说,研究人员应该进一步研究,扩大调查范围,增加深度,从而确定雄性激素、早秃与前列腺癌的关系。(生物谷Bioon.com)
生物谷推荐原文出处:
Ann Oncol (2011) doi: 10.1093/annonc/mdq695
Male pattern baldness and the risk of prostate cancer
M. Yassa1, M. Saliou1, Y. De Rycke2, C. Hemery3, M. Henni1, J. M. Bachaud4, N. Thiounn5, J. M. Cosset3 and P. Giraud3,6,*
Abstract
Background: Androgens play a role in the development of both androgenic alopecia, commonly known as male pattern baldness, and prostate cancer. We set out to study if early-onset androgenic alopecia was associated with an increased risk of prostate cancer later in life.
Patients and methods: A total of 669 subjects (388 with a history of prostate cancer and 281 without) were enrolled in this study. All subjects were asked to score their balding pattern at ages 20, 30 and 40. Statistical comparison was subsequently done between both groups of patients.
Results: Our study revealed that patients with prostate cancer were twice as likely to have androgenic alopecia at age 20 [odds ratio (OR) 2.01, P?=?0.0285]. The pattern of hair loss was not a predictive factor for the development of cancer. There was no association between early-onset alopecia and an earlier diagnosis of prostate cancer or with the development of more aggressive tumors.
Conclusions: This study shows an association between early-onset androgenic alopecia and the development of prostate cancer. Whether this population can benefit from routine prostate cancer screening or systematic use of 5-alpha reductase inhibitors as primary prevention remains to be determined.